| Title |
Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, January 2013
|
| DOI | 10.2147/copd.s37486 |
| Pubmed ID | |
| Authors |
Yevgeniy Samyshkin, Michael Schlunegger, Susan Haefliger, Sabine Ledderhose, Matthew Radford |
| Abstract |
Chronic obstructive pulmonary disease (COPD) represents a burden on patients and health systems. Roflumilast, an oral, selective phosphodiesterase-4-inhibitor reduces exacerbations and improves lung function in severe/very severe COPD patients with a history of exacerbations. This study aimed to estimate the lifetime cost and outcomes of roflumilast added-on to commonly used COPD regimens in Switzerland. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 50% |
| Spain | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 5% |
| Unknown | 60 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 22% |
| Student > Ph. D. Student | 7 | 11% |
| Other | 6 | 10% |
| Student > Master | 6 | 10% |
| Student > Bachelor | 5 | 8% |
| Other | 11 | 17% |
| Unknown | 14 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 41% |
| Economics, Econometrics and Finance | 9 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Agricultural and Biological Sciences | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#7,356,343
of 25,374,917 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#863
of 2,577 outputs
Outputs of similar age
#72,739
of 289,007 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#5
of 15 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,007 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.